Breast

GS-US-595-6184 at https://clinicaltrials.gov/study/NCT05633654

A randomized, open-label, phase 3 study of adjuvant sacituzumab govitecan (Trodelvy®) and pembrolizumab (Keytruda®) vs. treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy

Cancer Type: Breast triple negative

Principal Investigator: Dr. Debra Brandt

NRG – BR009 at https://clinicaltrials.gov/study/NCT05879926?term=NCT05879926&rank=1

NCT05879926

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to ovarian Function Suppression plus Endocrine therapy in Premenopausal Patients with pN0-, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤25 (OFSET)

Cancer Type: Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25

Principal Investigator: Dr. Debra Brandt

NRG – S2212 at https://clinicaltrials.gov/study/NCT05929768

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer, a Randomized Phase III Study

Cancer Type: Triple Negative Breast Cancer

Principal Investigator: Dr. Debra Brandt

A012303 - https://www.clinicaltrials.gov/study/NCT06876714?term=a012303&rank=1

Ph 3 Adjuvant trial evaluating the addition of adjuvant chemotherapy to ovarian function suppression plus endocrine therapy in premenopausal patients.

Principal Investigator: Dr. Danielle Krol

A012301 - https://www.clinicaltrials.gov/study/NCT06671912?term=a012301&rank=1

Ph 3 Clinical trial of low-dose Tamoxifen for selected patients with low-risk early-stage breast cancer.

Principle Investigator: Dr. Danielle Krol

Please contact Clinical Trials Office for more details: 561-263-5791

CLEE011O12001 (WIDER)

https://clinicaltrials.gov/study/NCT05827081?term=nct05827081&viewType=Card&rank=1

NCT 05827081

A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer (Adjuvant WIDER)

Principle Investigator: Dr. Danielle Krol, MD

Please contact Clinical Trials Office for more details: 561-263-5791

SIGNAL-ER 101 (25-085-NCP)

https://clinicaltrials.gov/study/NCT07214532?term=25-085-NCP&viewType=Card&rank=1

NCT07214532

Signatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer

Principle Investigator: Dr. Danielle Krol, MD

Please contact Clinical Trials Office for more details: 561-263-5791